Sublingual Allergy Immunotherapy Market Size, Share, and Growth Forecast, 2025 - 2032

The sublingual allergy immunotherapy (SLIT) market reached US$ 1,003.90 million in 2024 and is predicted to expand at a CAGR of 9.2% to climb to US$ 2,022.40 million by the end of 2032.

• As assessed by Persistence Market Research, the Odactra drug held a market share of 40.1% in 2024.
• Sublingual allergy immunotherapy accounted for 2% share of the global allergy treatment market in 2024.

In recent years, the prevalence of food allergies, allergic rhinitis, and other atopic illnesses like atopic dermatitis and allergic rhinitis has been on the rise.

• As per a 2019 study published in the National Library of Medicine, 20% of the world's population is now collectively impacted by allergic disorders.

Focus on innovation in sublingual immunotherapies in developing nations and increased prevalence of various forms of allergies are primary market drivers.

• According to the CDC (Centers for Disease Control and Prevention), food allergies are increasing rapidly, especially among children. Increasing allergy cases are expected to boost the demand for allergy immunotherapy over the forecast period.

The SLIT market is growing as a result of the expanding accessibility of advanced technology including molecular diagnostics and genetic testing. These innovations enhance patient outcomes by promoting precise diagnosis and individualized therapy planning.

Over the forecast period, market growth is expected to be driven by the increasing acceptance of advanced medical technologies and the rapid expansion of groundbreaking treatments in emerging countries.

Investments in research and technological advancements by key players for the commercialization of allergy immunotherapy products are expected to rise, leading to more advanced and specific treatment options. Manufacturers are directing their efforts toward research to develop immunotherapy treatments for food allergies. More than 40 products are in clinical trials and are expected to be commercialized in the next 2 to 3 years.

“Growing Burden of Allergic Diseases and Rising Awareness of Food Allergies”

Prevalence of allergic rhinitis, skin, asthma, insect, medication, or food allergies is increasing significantly.

• As per the American College of Allergy, Asthma & Immunology (2023), more than 50 million people in the United States experience allergic reactions annually, ranking allergies as the sixth most common chronic illness.

For short-term relief, people turn to drugs and sensitization techniques, but there are now just a few treatments available. Consequently, relieving allergy symptoms requires a sustained reliance on drugs. The uptake of these therapies is being aided by the accessibility of cutting-edge diagnostic techniques including serum-specific immunoglobulin E (IgE) testing and skin prick tests.

Food allergy is a critical and expanding public health concern as the prevalence of allergic disorders has dramatically increased in recent years.

• According to insights from Food Allergy Research & Education in 2023, there is an increasing prevalence of food allergies, with approximately 32 million Americans currently experiencing this condition.
• Food Allergy Awareness Week, which is observed by FARE every May, is a full week devoted to educating people and raising awareness about food allergies in general. The market for allergy immunotherapy is anticipated to expand as food allergy awareness rises.

Regulatory approval and commercialization of medications and therapies are creating opportunities for manufacturers. Products containing allergens are sold in several countries around the world, but the laws governing these sales vary. The number of allergic rhinitis treatments on the market has grown as a result of an increase in Abbreviated New Drug Application (ANDA) approvals for these drugs.

These factors are expected to contribute to the demand for more advanced and convenient allergy treatment options such as SLIT.

“High Treatment Cost and Unfavourable Side Effects of Some Medications”

Allergy shots are periodic injections administered over a period. Allergy immunotherapy is a lengthy treatment and may continue for up to 3 to 5 years to stop or reduce allergy attacks, depending on the type and stage of allergy.

A tiny amount of the specific substance or compounds that cause allergic reactions are present in each allergy shot. Patients undergoing the treatment usually discontinue the process midway due to prolonged treatment time, age, health, physical location, and budget constraints. This can negatively impact market growth for SLIT.

Allergy immunotherapy is a prolonged process and hence the cost associated with it also becomes a burden for patients.

• Allergy shots, SLIT, and oral therapy (Palforzia) can cost US$ 1,000, US$ 7,000, and US$ 4,000 per year, respectively, if not covered under insurance. Combination therapy is also expensive.

Patients have reported redness or swelling at the injection site and serious reactions such as anaphylaxis. Adverse effects associated with allergy shots and tablets are also limiting the demand for sublingual allergy immunotherapy.

What Makes Germany a Lucrative Market for Manufacturers of Sublingual Allergy Immunotherapy Drugs?

“Well-Established Regulatory Framework for Governing Medications for Allergies”

Germany accounted for 61.9% share of the European market in 2024.

Allergic disorders, including allergic rhinitis, affect a significant portion of the population in Germany. The country has a high prevalence of allergies, particularly due to the presence of allergens such as pollen, dust mites, and animal dander. This has created a substantial demand for effective treatments, including sublingual allergy immunotherapy.

Germany has a well-established regulatory framework for sublingual allergy immunotherapy. The Federal Institute for Drugs and Medical Devices (BfArM) oversees the approval and regulation of sublingual immunotherapy drugs in the country. A variety of treatment options are available to healthcare professionals and patients, as several sublingual immunotherapy drugs have been approved and are widely accessible.

What is the Demand Outlook for SLIT in the United States?

“Growing Public Awareness about Allergies and Widespread Availability of Effective Long-term Solutions”

The United States held 80% share of the North American SLIT market in 2024.

Increasing prevalence of allergic diseases contributed to the demand for effective treatments, including sublingual allergy immunotherapy. Many individuals are seeking long-term solutions that address the underlying causes of their allergies, and sublingual immunotherapy offers a viable option.

Various pharmaceutical companies are actively involved in the development, manufacturing, and distribution of sublingual allergy immunotherapy drugs in the U.S. These companies invest in research to develop effective formulations to expand the range of allergens covered by their products. They also engage in marketing and promotional activities to raise awareness and drive sales.

How is Demand for Sublingual Allergy Immunotherapy Shaping Up in China?

“Government Initiatives Promoting Adoption of Sublingual Immunotherapy for Allergy Management”

China accounted for 30.1% share of the East Asia market in 2024.

With increasing awareness about allergies and improved access to healthcare services, more individuals in China are seeking diagnosis and treatment for their allergic conditions. This has created a larger patient pool for SLIT treatments. The Chinese government has recognized the importance of allergy management and has been taking initiatives to promote the use of SLIT. They have been encouraging research, development, and registration of SLIT products, as well as providing guidelines for their use.

Which Sublingual Allergy Immunotherapy Drug Accounts for High Demand?

“High Demand for Odactra Due to its Efficacy, Convenience, and Accessibility as Immunotherapy Treatment for House Dust Mite Allergic Rhinitis”

The drug Odactra accounted for 40.1% sales in 2024.

Odactra is a sublingual immunotherapy (SLIT) medication used for the treatment of allergic rhinitis caused by house dust mites. Odactra offers a convenient alternative to traditional allergy shots (subcutaneous immunotherapy). It can be self-administered at home after an initial prescription and guidance from a healthcare professional.

Availability of sublingual immunotherapy treatments like Odactra has increased access to allergy treatment for individuals who may not have easy access to allergists or immunotherapy clinics.

Why Does Allergic Rhinitis Occupy a Leading Market Share?

“Increasing Prevalence of Allergic Rhinitis Pushing Demand for Effective SLIT Solutions”

Allergic rhinitis indication held 43.3% share of the global market in 2024.

Allergic rhinitis is a common condition worldwide, affecting a significant portion of the population. It is characterized by symptoms such as sneezing, itching, nasal congestion, and runny nose triggered by allergens such as pollen, dust mites, or animal dander. The prevalence of allergic rhinitis has been increasing, leading to a higher demand for effective treatments like SLIT.

Which Allergen-based Segment Generates High Demand for SLIT?

“Increasing Prevalence of Pollen Allergies Necessitating Development of Effective Immunotherapy Solutions”

Demand for SLIT solutions for pollen allergy accounted for 52.2% of the global market share in 2024.

Pollen allergies, also known as hay fever or seasonal allergic rhinitis, are a common form of allergic rhinitis triggered by the pollen from trees, grasses, and weeds. Sublingual allergy immunotherapy has emerged as an effective treatment option for pollen allergies, and as a result, there is a growing market for sublingual immunotherapy specifically targeting pollen allergies. The market for sublingual allergy immunotherapy for pollen allergies has been expanding due to the increasing prevalence of pollen allergies worldwide. Pollen allergies affect a significant portion of the population, particularly during specific seasons when pollen is abundant in the air.

Manufacturers of SLIT drugs are striving to expand into new areas and maintain their relationships with distributors.

Some key instances of developments in this regard include:

• In April 2020, Health Canada granted authorization to ALK Abello for the use of ITULATEK, a sublingual tablet, as a treatment for tree pollen allergy.
• In 2021, Stallergenes Greer and Aptar Pharma joined forces to develop an innovative connected device for the delivery of allergen immunotherapy treatments.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the sublingual allergy immunotherapy market, which are available in the full report.